Alligator Bioscience appoints Søren Bregenholt as new CEO
Lund, Sweden, March 18, 2021 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that the Board of Directors has appointed Søre ...
Alligator Bioscience publishes Annual Report for 2020
Lund, Sweden, March 18, 2021 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that the Annual Report for 2020 has been publi ...
Change in number of shares and votes in Alligator Bioscience AB
During February 2021, the number of shares and votes in Alligator Bioscience AB (“Alligator”) has increased as a result of the completion of ...
Alligator Bioscience AB: Year-end Report January-December 2020
Continued focus on clinical development. “Safety data has been presented from the ongoing Phase I study with ATOR-1017 in patients with meta ...
Alligator Bioscience’s rights issue oversubscribed
Alligator Bioscience AB (publ) (“Alligator” or the “Company”) has completed the share issue with pre-emption rights for the Company’s shareh ...
Alligator carries out a fully guaranteed rights issue of approximately SEK 86m
The Board of Directors of Alligator Bioscience AB (publ) ("Alligator" or the "Company") has today, based on the authorizatio ...
Predicted therapeutic range dose levels reached in ATOR-1017 Phase I
Lund, Sweden, October 27, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced additional positive interim safety data from ...
Alligator Bioscience AB (publ): Interim report January-September 2020
Encouraging clinical safety data for ATOR-1017 The Phase I study with ATOR-1017 has progressed exceptionally well and in August we presented ...
Alligator Bioscience focuses on ATOR-1017 and mitazalimab
Lund, Sweden, October 22, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced the decision to focus its resources on the t ...